Patient recruitment underway in phase 2a trial for cannabis oil dementia treatment

 With your elevated risk of dementia post stroke, if your doctor isn't closely following this research you don't have a functioning stroke doctor or hospital. Don't do anything with this until your doctor oks it.

Your risk of dementia, has your doctor told you of this?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

What is your doctor's EXACT PROTOCOL TO PREVENT DEMENTIA?

The latest here:

Patient recruitment underway in phase 2a trial for cannabis oil dementia treatment 

MediCane Health Inc. announced recruitment of the first patient for its phase 2a study designed to assess the effects of cannabis oil in adults with probable Alzheimer’s disease who have limited or no response to antipsychotic medication.

According to a company release, the trial is being conducted in two leading academic hospitals in Israel — Sheba Medical Center and Sourasky Medical Center. The trial will include 55 participants, who will receive MediCane’s balanced THC:CBD orally administered cannabis oil extracted from MediCane’s proprietary strain and formulated for blinding purposes, in addition to standard care.

MediCane Health Inc. will soon commence a phase 2a clinical trial to test its proprietary oral medical cannabis oil on patients with behavioral and psychological symptoms of dementia. Source: Adobe Stock.

The first part of the study is an open-label phase that will enroll 15 participants for safety and dose-range finding, followed by a randomized, double-blind, placebo-controlled second phase that will include 40 participants to evaluate safety and efficacy, the company stated.

According to the release, agitation and disruptive behaviors, expressed as excessive fidgeting, restlessness, pacing, shouting, screaming, uninhibited behaviors and aggression, are present in over half of patients with dementia at some point during the illness.

“MediCane is proud to collaborate with two of the leading medical centers in Israel in our journey to find a safe and effective cannabis-based medicine for [behavioral and psychological symptoms of dementia] symptom relief,” Nurit Tweezer-Zaks, MD, MBA, CEO of MediCane research and development, said in the release. “Through this joint effort we hope to be able to successfully complete the study during 2024 and launch the product in Israel, Germany and additional EU markets.”